Mineralys Therapeutics Inc’s filing revealed that its Chief Medical Officer Rodman David Malcom unloaded Company’s shares for reported $0.88 million on Apr 01 ’25. In the deal valued at $15.76 per share,55,771 shares were sold. As a result of this transaction, Rodman David Malcom now holds 116,704 shares worth roughly $1.45 million.
Then, Rodman David Malcom bought 55,771 shares, generating $879,009 in total proceeds.
Before that, Samsara BioCapital GP, LLC bought 600,000 shares. Mineralys Therapeutics Inc shares valued at $8,100,000 were divested by the 10% Owner at a price of $13.50 per share. As a result of the transaction, Samsara BioCapital GP, LLC now holds 5,674,916 shares, worth roughly $70.37 million.
H.C. Wainwright initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on July 10, 2024; the price target was $30. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Wells Fargo began covering MLYS with “an Overweight” recommendation on March 07, 2023. Stifel started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.
Price Performance Review of MLYS
On Friday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -8.35% to $12.40. Over the last five days, the stock has lost -15.42%. Mineralys Therapeutics Inc shares have risen nearly 0.73% since the year began. Nevertheless, the stocks have fallen -3.88% over the past one year. While a 52-week high of $18.38 was reached on 03/19/25, a 52-week low of $8.24 was recorded on 02/25/25. SMA at 50 days reached $11.89, while 200 days put it at $12.25.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 11.80, which if violated will result in even more drops to 11.21. On the upside, there is a resistance level at 13.24. A further resistance level may holdings at 14.09. The Relative Strength Index (RSI) on the 14-day chart is 43.39, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.99, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.50%. Stochastics %K at 11.31% indicates the stock is a buying.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-03-14, growing by 0.47 million shares to a total of 2.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 1.75 million shares. There was a rise of 21.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
